Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis

In 215 patients with a median age of 16 years, fingolimod was superior to interferon beta-1a in reducing relapses of multiple sclerosis and the accumulation of new lesions on MRI over a 2-year period. Seizures occurred in 5.6% of patients in the fingolimod group.

Saved in:

Bibliographic Details
Published in:	The New England journal of medicine Vol. 379; no. 11; pp. 1017 - 1027
Main Authors:	Chitnis, Tanuja, Arnold, Douglas L, Banwell, Brenda, Brück, Wolfgang, Ghezzi, Angelo, Giovannoni, Gavin, Greenberg, Benjamin, Krupp, Lauren, Rostásy, Kevin, Tardieu, Marc, Waubant, Emmanuelle, Wolinsky, Jerry S, Bar-Or, Amit, Stites, Tracy, Chen, Yu, Putzki, Norman, Merschhemke, Martin, Gärtner, Jutta
Format:	Journal Article
Language:	English
Published:	United States Massachusetts Medical Society 13.09.2018
Subjects:	Adults Age Body weight Clinical trials Convulsions FDA approval Interferon Leukopenia Life Sciences Magnetic resonance imaging Multiple sclerosis NMR Nuclear magnetic resonance Patients Pediatrics Regulatory approval Tachycardia Technical communication β-Interferon Headache Immunologic Factors Brain Administration Relapsing-Remitting Interferon-beta Leukopenia Humans Fingolimod Hydrochloride Male Secondary Prevention Oral Intramuscular Multiple Sclerosis Infection Magnetic Resonance Imaging Injections Adolescent Female Child
ISSN:	0028-4793, 1533-4406, 1533-4406
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!